N-benzyl-1-cyclopropyl methanimine | 275800-36-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-benzyl-1-cyclopropyl methanimine
• 英文别名: N-(cyclopropylmethylene)benzenemethanamine；N-benzyl-1-cyclopropylmethanimine
• CAS: 275800-36-7
• 化学式: C₁₁H₁₃N
• 分子量: 159.231
• InChiKey: XTUJHZMCQVDWFH-UHFFFAOYSA-N

物化性质

• 沸点：
  265.7±23.0 °C(Predicted)
• 密度：
  1.01±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  12.4
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-benzyl-1-cyclopropyl methanimine 在 三乙烯二胺 、 platinum(IV) oxide 、 氢气 、 scandium tris(trifluoromethanesulfonate) 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 84.0h， 生成 trans-1-benzyl-2-cyclopropylpyrrolidin-3-amine
  参考文献：
  名称：

  [EN] SUBSTITUTED PYRROLIDINE AMIDES V
  [FR] AMIDES DE PYRROLIDINE SUBSTITUÉS V

  摘要：

  公开号：

  WO2020254552A4
• 作为产物：
  描述：

  苄胺 、 环丙甲醛 在 magnesium sulfate 作用下， 以 二氯甲烷 为溶剂， 反应 48.0h， 以100%的产率得到N-benzyl-1-cyclopropyl methanimine
  参考文献：
  名称：

  [EN] PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
  [FR] COMPOSÉS DE PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES MÉDICAUX

  摘要：

  本发明提供了取代的吡唑[1,5-a]嘧啶基甲酰胺及其相关有机化合物，包含此类化合物的组合物，医疗包，以及使用此类化合物和组合物治疗医疗障碍的方法，例如，戈谢病，帕金森病，路易体病，痴呆症或多系统萎缩症。所述的代表性的取代吡唑[1,5-a]嘧啶基甲酰胺化合物包括2-杂环基-4-烷基-吡唑[1,5-a]嘧啶-3-甲酰胺化合物及其变体。

  公开号：

  WO2017176960A1

文献信息

• Palladium‐Catalyzed Carbonylative Difunctionalization of C=N Bond of Azaarenes or Imines to Quinazolinones
  作者：Xibing Zhou、Yongzheng Ding、Hanmin Huang

  DOI：10.1002/asia.202000359

  日期：2020.6.2

  Supporting information for this article is given via a link at the end of the document. By intercepting the acylpalladium species with C=N bond of azaarenes or imines other than free amines or alcohols, the difunctionalization of C=N bond was established via palladium‐catalyzed carbonylation/nucleophilic addition sequence. This method is compatible with a diverse range of azaarenes and imines and allows

  本文末尾的链接提供了本文的支持信息。通过用氮杂芳烃或亚胺的C = N键（除游离胺或醇以外）拦截酰基铝物种，可通过钯催化的羰基化/亲核加成序列建立C = N键的双官能化。该方法与各种范围的氮杂芳烃和亚胺兼容，并允许有效合成范围广泛的喹唑啉酮及其衍生物。通过廉价的原料一步一步合成乙二胺及其类似物，已证明了其合成用途。
• [EN] IMIDAZO [1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS<br/>[FR] COMPOSÉS IMIDAZO [1,5-A]PYRIMIDINYL CARBOXAMIDE ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES MÉDICAUX
  申请人：LYSOSOMAL THERAPEUTICS INC

  公开号：WO2017176961A1

  公开（公告）日：2017-10-12

  The invention provides substituted imidazo[1,5-a]pyrimidinyl carboxamide and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted imidazo[1,5-a]pyrimidinyl carboxamide compounds described herein include substituted 2-heterocyclyl-4-alkyl-imidazo[1,5-a]pyrirnidine-8-carboxamide compounds and variants thereof.

  本发明提供了取代的咪唑[1,5-a]嘧啶基甲酰胺及其相关有机化合物，包含此类化合物的组合物，医疗试剂盒，以及使用此类化合物和组合物治疗医疗障碍的方法，例如，戈谢病，帕金森病，路易体病，痴呆症或多系统萎缩症。本说明书中描述的代表性的取代咪唑[1,5-a]嘧啶基甲酰胺化合物包括取代的2-杂环基-4-烷基-咪唑[1,5-a]嘧啶-8-甲酰胺化合物及其变体。
• [EN] PYRROLO[1,2-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS<br/>[FR] COMPOSÉS PYRROLO[1,2-A]PYRIMIDINYL CARBOXAMIDE ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES MÉDICAUX
  申请人：LYSOSOMAL THERAPEUTICS INC

  公开号：WO2017176962A1

  公开（公告）日：2017-10-12

  The invention provides substituted pyrrolo[1,2-a]pyrimidinyl carboxamide and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted pyrrolo[1,2-a]pyrimidinyl carboxamide compounds described herein include substituted 2-heterocyclyl-4-alkyl-pyrrolo[1,2-a]pyrimidine-8-carboxarnide compounds and variants thereof.

  该发明提供了取代的吡咯并[1,2-a]嘧啶基甲酰胺和相关的有机化合物，含有这些化合物的组合物，医疗工具包，以及使用这些化合物和组合物来治疗医学疾病的方法，例如高雪氏病，帕金森病，劳伊氏体病，痴呆症或多系统萎缩症等患者。本文描述的示例取代的吡咯并[1,2-a]嘧啶基甲酰胺化合物包括取代的2-杂环基-4-烷基-吡咯并[1,2-a]嘧啶-8-甲酰胺化合物及其变体。
• Nitrile Biotransformations for the Synthesis of Highly Enantioenriched β-Hydroxy and β-Amino Acid and Amide Derivatives: A General and Simple but Powerful and Efficient Benzyl Protection Strategy To Increase Enantioselectivity of the Amidase
  作者：Da-You Ma、De-Xian Wang、Jie Pan、Zhi-Tang Huang、Mei-Xiang Wang

  DOI：10.1021/jo800074k

  日期：2008.6.1

  Biotransformations of a number of racemic beta-hydroxy and beta-amino nitrile derivatives were studied using Rhodococcus erythropolis AJ270, the nitrile hydratase and amidase-containing microbial whole cell catalyst, under very mild conditions. The overall enantioselectivity of nitrile biotransformations was governed predominantly by the amidase whose enantioselectivity was switched on remarkably by an O- and a N-benzyl protection group of the Substrates. While biotransformations of beta-hydroxy and beta-amino alkanenitriles gave low yields of amide and acid products of very low enantiomeric purity, introduction of a simple benzyl protection group on the beta-hydroxy and beta-amino of nitrile substrates led to the formation of highly enantioenriched beta-benzyloxy and beta-benzylamino amides and acids in almost quantitative yield. The easy protection and deprotection operations, high chemical yield, and excellent enantioselectivity render the nitrile biotransformation a useful protocol in the synthesis of enantiopure beta-hydroxy and beta-amino acids.
• Computer-Assisted Design of Selective Imidazole Inhibitors for Cytochrome P450 Enzymes
  作者：Andreas Verras、Irwin D. Kuntz、Paul R. Ortiz de Montellano

  DOI：10.1021/jm030608t

  日期：2004.7.1

  A modified version of the DOCK program has been used to predict inhibitors for cytochrome P450cam and its L244A mutant. A library of azole compounds was designed in silico and screened for binding to wild-type P450cam. Lead compounds were synthesized and found to inhibit wild-type P450cam. To test our approach to designing ligands that discriminate between closely related sites, the azole library was DOCKed into both the active sites of wild-type P450cam and its L244A mutant. The L244A active site is predicted to be slightly larger than that of wild-type P450cam. Ligands predicted to have a high affinity for the mutant alone were synthesized and assayed with the recombinant enzymes. All of the compounds showed inhibition of the L244A enzyme (IC50 = 6-40 muM), and the compounds that were predicted to be too large to bind to the wild-type showed poor inhibition (IC50 greater than or equal to 1 mM). The binding mode was shown to be similar to that predicted by our modified version of DOCK by spectroscopic analysis. A discrepancy between the IC50 values and spectroscopic K-s values indicates that the spectroscopic binding constants do not accurately estimate inhibitory activity. This study, the first report of computer-assisted ligand (drug) design for P450 enzymes in which the coordination bond between imidazole and the heme is explicitly considered in structural modeling, opens a promising design avenue because azole compounds are widely used as P450 enzyme inhibitors and drugs.